IDEXX Laboratories, Inc.
HealthcareNASDAQ:IDXX · NASDAQ Global Select
+$1.46 today
Vol 0.23M · Avg 0.58M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$4.4B of revenue converted into $1.1B of net income for the selected period. Gross margin is 62.0% and net margin is 24.6%, showing how much revenue survives after costs and taxes. EPS is $13.56, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.3B +10.4% | $3.9B +6.5% | $3.7B +8.7% | $3.4B +4.7% | $3.2B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.6B +8.3% | $1.5B +3.2% | $1.5B +7.9% | $1.4B +2.8% | $1.3B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $2.7B +11.8% | $2.4B +8.6% | $2.2B +9.3% | $2.0B +6.1% | $1.9B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 61.8% +0.8pp | 61.0% +1.2pp | 59.8% +0.3pp | 59.5% +0.8pp | 58.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $251.2M +14.3% | $219.8M +15.1% | $191.0M -25.1% | $254.8M +58.3% | $161.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.0B +1.7% | $1.0B +14.3% | $901.9M +6.0% | $850.8M +6.8% | $796.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.3B +3.9% | $1.3B +14.4% | $1.1B -1.2% | $1.1B +15.5% | $957.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $106.5M -18.1% | $129.9M +13.1% | $114.9M +2.7% | $111.9M +7.0% | $104.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.5B +15.1% | $1.3B +4.8% | $1.2B +20.0% | $1.0B -2.4% | $1.0B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 34.1% +1.4pp | 32.7% -0.5pp | 33.3% +3.1pp | 30.1% -2.2pp | 32.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.4B +20.5% | $1.1B +2.8% | $1.1B +22.1% | $898.8M -3.6% | $932.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 31.6% +2.7pp | 29.0% -1.0pp | 30.0% +3.3pp | 26.7% -2.3pp | 29.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.4M -80.9% | $12.7M +125.6% | $5.6M +428.5% | $1.1M +145.4% | $434.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $38.3M +22.6% | $31.2M -25.0% | $41.6M +4.3% | $39.9M +33.7% | $29.8M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$35.8M -93.7% | -$18.5M +48.5% | -$36.0M +7.3% | -$38.8M -32.1% | -$29.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.3B +19.3% | $1.1B +4.6% | $1.1B +23.4% | $860.0M -4.7% | $902.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 30.8% +2.3pp | 28.5% -0.5pp | 29.0% +3.4pp | 25.5% -2.5pp | 28.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $264.7M +19.3% | $222.0M +2.7% | $216.1M +19.5% | $180.9M +14.6% | $157.8M | $1.3B | -$1.6B | $745.2M |
| Net Income | $1.1B +19.3% | $887.9M +5.1% | $845.0M +24.4% | $679.1M -8.8% | $744.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | 24.6% +1.8pp | 22.8% -0.3pp | 23.1% +2.9pp | 20.2% -3.0pp | 23.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $13 +22.3% | $11 +5.9% | $10 +25.2% | $8 -7.1% | $9 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $13 +22.6% | $11 +6.1% | $10 +25.3% | $8 -6.6% | $9 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $80.1M -2.9% | $82.5M -0.7% | $83.1M -0.7% | $83.6M -1.9% | $85.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $80.7M -3.1% | $83.2M -0.9% | $84.0M -0.7% | $84.6M -2.3% | $86.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
argenx SE
NASDAQ:ARGX
$55.60B
Cencora, Inc.
NYSE:COR
$54.90B
Becton, Dickinson and Company
NYSE:BDX
$52.82B
Cardinal Health, Inc.
NYSE:CAH
$52.34B
Edwards Lifesciences Corporation
NYSE:EW
$48.80B
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
$37.89B
Agilent Technologies, Inc.
NYSE:A
$36.54B
Zoetis Inc.
NYSE:ZTS
$33.66B
IQVIA Holdings Inc.
NYSE:IQV
$29.85B
Veeva Systems Inc.
NYSE:VEEV
$25.83B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does IDXX generate?
IDEXX Laboratories, Inc. (IDXX) reported $4.30B of revenue in fiscal 2025.
Is IDXX profitable?
IDEXX Laboratories, Inc. (IDXX) reported $1.06B of net income, with a net margin of 24.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.